AgingResearch.NewsJoin free

MAB47

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 2 of 2 findings with company ties
  • Animals1

Outcomes

2

Lifespan

upin mice1

1 study

  1. MAB47 extends lifespan in mice.

    “mAb47 treatment of α-synuclein transgenic mice resulted in a significantly prolonged survival.”

    Animalsα-synuclein transgenic mice

    ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

    Neurobiology of disease1 Nov 2021

Alpha-synuclein aggregates

downin mice1

1 study

  1. MAB47 decreases alpha-synuclein aggregates in mice.

    “displayed significant dose-dependent decrease of α-synuclein aggregates in brain in several mouse models”

    Animalsα-synuclein transgenic micebrain

    ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

    Neurobiology of disease1 Nov 2021

More on Alpha-synuclein aggregates

Latest

Related